Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BaEVTR lentiviral vector
- Development stage
- Preclinical
- Lead developer
- Vector Biomed
- Modality
- Lentiviral Vectors → Retroviral Vectors → Viral Vectors → Gene Addition/Replacement → Gene Therapies
- Administration
- Intravenous, Ex Vivo
01
Overview
BaEVTR lentiviral vector is a gene therapy delivery platform consisting of a lentiviral vector pseudotyped with a modified baboon endogenous retrovirus (BaEV) envelope glycoprotein. The modification involves replacing the BaEV cytoplasmic tail with that of the amphotropic murine leukemia virus (MLV-A) to facilitate efficient incorporation into lentiviral particles. This vector targets the sodium-dependent neutral amino acid transporters ASCT-1 (SLC1A4) and ASCT-2 (SLC1A5), which are expressed on the surface of quiescent hematopoietic cells. Unlike conventional VSV-G pseudotyped vectors, BaEVTR-LV allows for high-efficiency transduction of resting T cells, B cells, NK cells, and hematopoietic stem cells (HSCs) without requiring ex vivo activation or cytokine stimulation. It is being developed for various applications, including the treatment of primary immunodeficiencies, hemoglobinopathies, and the engineering of CAR-NK cells.
- Other names
- BaEVTR pseudotyped lentiviral vectorbaboon endogenous retrovirus-pseudotyped lentiviral vector
02
Targets
ASCT1 (Neutral amino acid transporter A)SLC1A5 (Alanine/serine/cysteine transporter 2)
Beyond the preview
Go deeper on BaEVTR lentiviral vector.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BaEVTR lentiviral vector.